Monitor for defendants' responses, potential ANDA filings, and any Markman hearings or summary judgment rulings that could clarify patent scope and timeline to generic entry.
Price Chart
Executive Summary
Xeris Biopharma filed patent infringement lawsuits against Torrent Pharma, Cycle Pharmaceuticals, Rising Pharma, and related entities following the grant of U.S. Patent No. 12,758,502 covering its KEVEYIS (dichlorphenamide) product. The lawsuits seek injunctive relief and monetary damages to block generic competition. This is an early-stage patent enforcement action with no immediate financial exposure or revenue impact.
Key Facts
- Filed two separate patent infringement lawsuits in the U.S. District Court for the District of New Jersey on October 13, 2026.
- Defendants include Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
- Lawsuits follow the grant of U.S. Patent No. 12,758,502 related to KEVEYIS (dichlorphenamide).
- Alleges willful infringement by defendants' generic dichlorphenamide products.
- Seeks judgment of infringement, injunctive relief, monetary damages, enhanced damages, attorneys' fees, and costs.
Financial Impact
No specific damages or revenue figures disclosed; potential to protect KEVEYIS market exclusivity if successful.
Risk Factors
- Risk that the patent is invalidated or not infringed, opening the door to generic competition.
- Litigation costs and management distraction with no guaranteed outcome.
- Potential for adverse rulings that could shorten effective patent life for KEVEYIS.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001867096-26-000091 |
| Document: 0001867096-26-000091-index-headers.html | 0001867096-26-000091 |
| Document: 0001867096-26-000091-index.html | 0001867096-26-000091 |
| Document: 0001867096-26-000091.txt | 0001867096-26-000091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $9.77 | awaiting T+20 | — | $10.21 (+4.50%) |
Oct 2, 2026 24d ago | Insider Cluster | $10.13 | awaiting T+20 | — | $10.21 (+0.79%) |
Oct 1, 2026 25d ago | 144 | $9.08 | awaiting T+20 | — | $10.21 (+12.44%) |
Sep 9, 2026 6w ago | 8-K | $7.71 $10.11 | ▲ +31.13% | ▲ +29.18% | $10.21 (+32.43%) |
Sep 1, 2026 7w ago | Insider Cluster | $8.58 $9.56 | ▲ +11.42% | ▲ +11.51% | $10.21 (+19.00%) |
Aug 6, 2026 11w ago | 8-K | $7.36 $8.59 | ▲ +16.71% | ▲ +16.11% | $10.21 (+38.72%) |
Aug 4, 2026 11w ago | Insider Cluster | $8.11 $8.58 | ▲ +5.80% | ▲ +6.40% | $10.21 (+25.89%) |
Jul 7, 2026 15w ago | Insider Cluster | $8.67 $8.11 | ▲ +6.46% | ▲ +9.73% | $10.21 (−17.76%) |
Jul 2, 2026 16w ago | 3 | $8.28 $8.42 | ▲ +1.69% | ▲ +2.11% | $10.21 (+23.31%) |
Jul 2, 2026 16w ago | Insider Cluster | $8.37 $8.13 | ▼ −2.87% | ▼ −3.72% | $10.21 (+21.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers